Company profile: Prime Medicine
1.1 - Company Overview
Company description
- Provider of gene editing technologies and therapies utilizing Prime Editing to modify genetic sequences to treat a wide range of diseases. Offerings include Prime Editors for precise edits across tissues and cell types, Dual Flap Prime Editing for broader edits, PASSIGE for inserting large gene-sized sequences, and Prime-Edited Cell Therapy.
Products and services
- Prime Editing: A custom-engineered gene-editing platform that searches and replaces DNA sequences at exact genomic loci without double‑strand breaks, enabling targeted modification to treat a wide range of diseases
- PASSIGE: A recombinase-assisted prime editing method combining integrase or site-specific recombinase to introduce large gene-sized DNA payloads into genomes as a single-administration therapy
- Prime-Edited Cell Therapy: A clinical-grade therapeutic approach applying prime editing to generate precise, targeted edits across diverse cell types, tissues, and organs for treating various genetic diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Prime Medicine
Cartana
HQ: Sweden
Website
- Description: Provider of in situ sequencing (ISS) technology to map gene expression in brain tissue, enabling simultaneous analysis of hundreds of genes across all cells in a tissue while preserving tissue morphology, with high sensitivity and throughput.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cartana company profile →
Identigen
HQ: Ireland
Website
- Description: Provider of DNA-based solutions to the agri-food industry, applying genetic identification to improve the quality, integrity and safety of the global food supply. Offers DNA TRACEBACK for verifying food origin and production practices, and DATALIVE for animal lifecycle insights to support sustainable business and environmental practices. Operates in Ireland, UK, EU, USA and Canada.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Identigen company profile →
Verge Genomics
HQ: United States
Website
- Description: Provider of an AI-powered, all-in-human drug discovery platform (CONVERGE®) integrating proprietary human genomics and computational tools to predict new drugs; developer of VRG50635, a PIKfyve inhibitor for ALS; and collaborator with industry and academic partners, including Alexion/AstraZeneca Rare Disease, Eli Lilly, and SITraN, to co-develop clinical-stage and novel therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verge Genomics company profile →
Exiqon
HQ: Denmark
Website
- Description: Provider of Life Sciences and Diagnostics solutions, offering flexible RNA analysis research products used by academia, biotech and pharmaceutical companies worldwide to investigate gene activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exiqon company profile →
Agendia
HQ: The Netherlands
Website
- Description: Provider of molecular diagnostics and personalized treatment planning for breast cancer, offering MammaPrint (70-gene analysis to assess recurrence risk, results in 6 days or less) and BluePrint (80-gene analysis to determine molecular subtype, results in less than 6 days). Supports research via the FLEX study and trials including SWOG S2206, INSIGHT, and I-SPY2.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agendia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Prime Medicine
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Prime Medicine
2.2 - Growth funds investing in similar companies to Prime Medicine
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Prime Medicine
4.2 - Public trading comparable groups for Prime Medicine
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →